VJHemOnc is committed to improving our service to you

Share this video  

VJHemOnc is committed to improving our service to you

MPN Advances Day 2017 | The future of predicting outcomes for patients with MPNs: a patient knowledge bank

The discovery of various molecular risk factors for myeloproliferative neoplasms (MPNs) has revolutionized the way in which doctors diagnose these diseases, and the way that they determine the prognosis. Speaking from the Myeloproliferative Neoplasms Advances Day 2017, London, UK, Tony Green, MD, PhD, of the University of Cambridge, Cambridge, UK, discusses some of the most important molecular discoveries that have changed the field of MPN diagnosis, such as the JAK2 V617F mutation. He also proposes a way in which the presence or absence of these mutations, combined with clinical data and outcomes, could be used to generate a patient knowledge bank, used to accurately predict new patient outcomes.

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter